HER-Vaxx has completed Ph2 clinical trial after releasing very good results at the start of this year and PD1-Vaxx has started Ph2 clinical trial at the end of last year. IMU will need another CR (touch and go depending on when the R&D rebates are received) to complete Ph1 clinical trial for VAXINIA and OASIS then they will need a bigger CR to start Ph2 clinical trials which is more expensive but I think BP will show interest end of Ph1 since CF33 has demonstrated exceptional toxicity profile so there's a bigger bandwidth to escalate the dosage much further and there's already efficacy shown so early in Ph1 on low dosage. As for Ph3, it was always too expensive to go alone unless they get registrational clinical trial status which they are planning for Azer-Cel.
IMU Price at posting:
4.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)